TEM · Company KPIs
Tempus AI (TEM) KPIs
Oncology volume growth (year-over-year). As reported in SEC filings, with the source line for each figure.
Oncology volume growth (year-over-year)
31% for the period ended Jun 30, 2026
The filings read for this page do not define this measure.
| Period ended | Figure | Filing text |
|---|---|---|
| Jun 30, 2026 | 31% | Oncology volume growth of 31% year-over-year, up from 28% last quarter8-K filed 2026-07-30 |
| Mar 31, 2026 | 28% | Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28%8-K filed 2026-05-05 |
| Dec 31, 2025 | 29% | Diagnostics revenue of ~$266 million, representing ~121% growth year-over-year, driven by Oncology volume growth of ~29% and Hereditary volume growth of ~23%8-K filed 2026-01-12 |
| Sep 30, 2025 | 27% | 217,000 clinical tests delivered in the quarter, representing 33% year-over-year volume growth, with Oncology volume growth accelerating to 27% and Hereditary at 37%8-K filed 2025-11-04 |
Reading notes
Figures are shown as first reported. If a later filing prints a different figure for the same period, both appear. A figure marked ≈ or shown in words is how the company itself states it, not an estimate of ours. Companies change definitions over time, so compare periods with the quoted definition in mind. Periods that failed our checks are left out, so gaps are expected.